Enzo Biochem Inc. (ENZ) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Enzo Biochem Inc. (NYSE:ENZ) issued its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. The company earned $26.60 million during the quarter, compared to the consensus estimate of $26 million. Enzo Biochem had a net margin of 17.27% and a negative return on equity of 20.77%. During the same quarter in the prior year, the firm posted ($0.06) EPS.
Enzo Biochem (NYSE:ENZ) opened at 5.07 on Friday. The company has a 50-day moving average of $5.34 and a 200 day moving average of $5.68. The company has a market cap of $234.56 million, a P/E ratio of 13.27 and a beta of 1.50. Enzo Biochem has a one year low of $3.48 and a one year high of $7.00.
Large investors have recently made changes to their positions in the stock. California Public Employees Retirement System increased its stake in shares of Enzo Biochem by 75.9% in the second quarter. California Public Employees Retirement System now owns 100,141 shares of the company’s stock worth $598,000 after buying an additional 43,200 shares in the last quarter. Emerald Acquisition Ltd. purchased a new stake in shares of Enzo Biochem during the second quarter worth approximately $573,000. KBC Group NV increased its stake in shares of Enzo Biochem by 207.8% in the second quarter. KBC Group NV now owns 20,551 shares of the company’s stock worth $123,000 after buying an additional 13,875 shares in the last quarter. California State Teachers Retirement System purchased a new stake in shares of Enzo Biochem during the second quarter worth approximately $497,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Enzo Biochem by 89.8% in the second quarter. Bank of New York Mellon Corp now owns 187,262 shares of the company’s stock worth $1,119,000 after buying an additional 88,602 shares in the last quarter. 53.29% of the stock is currently owned by institutional investors.
Separately, Zacks Investment Research raised shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a report on Thursday, June 16th.
Enzo Biochem Company Profile
Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.
Receive News & Stock Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related stocks with our FREE daily email newsletter.